Durability of Responses with Biweekly Dosing of Teclistamab

Studying teclistamab dosing in patients with relapsed myeloma

The study presented by Dr. Saad Usmani focuses on the durability of response with bi-weekly dosing of teclistamab in patients with relapse refractory multiple myeloma. teclistamab is a BCMA-directed specific antibody approved for triple class exposed relapse refractory multiple myeloma. The pivotal phase one two MajesTEC-1 trial showed a rapid and deep durable response rate of 63 percent with a median follow-up of 11.3 months.

• Teclistamab is the first BCMA-directed specific antibody approved for triple class exposed relapse refractory multiple myeloma.
• In the pivotal MajesTEC-1 trial, teclistamab demonstrated a rapid and deep durable response rate with an overall response rate of 63 percent.
• The median follow-up reported in the original paper was 11.3 months, but it has since increased to a median follow-up of nearly two years.
• Patients in the MajesTEC-1 trial who achieved and maintained a response were able to switch to a less frequent dosing schedule, offering convenience and flexibility to patients, caregivers, and physicians.
• A total of 165 patients were treated with teclistamab at the recommended phase two dose, and 104 patients responded.
• Of the responders, 63 patients switched to bi-weekly dosing, with 54 of them meeting the protocol-defined criteria for switching.
• The median time to switch was 11.3 months, and the median follow-up since switching was 12.6 months.
• The majority of patients who switched to bi-weekly dosing were in complete response (CR) or better, and nearly 70 percent remained in response for at least two years from the time of their first response.
• As of the data cutoff, 42 out of 63 patients who switched maintained their responses, 41 of whom are still ongoing with treatment.
• There was a reduction in new onset grade 3 or higher infections over time in patients on the bi-weekly dosing schedule compared to the weekly dosing schedule.

Authors:

Saad Zafar Usmani, Lionel Karlin, Lotfi Benboubker, Hareth Nahi, Jesús San-Miguel, Danielle Trancucci, Keqin Qi, Tara Stephenson, Alfredo Perales-Puchalt, Katherine Chastain, Ajai Chari

Clinical Trial Information: NCT03145181, NCT04557098